GSK Bio
NEWS
Biotech investor Neil Woodford is poised for a comeback after a fall from grace two years ago.
Under the terms of the deal, Sandoz is paying GSK $350 million at closing and additional milestones up to $150 million.
There are some big surprises among the list of major players in the vaccine space who either dropped their programs or have been significantly delayed.
Billionaire Sir Richard Branson believes in healthcare. This week he put more of his money where his mouth is by using his SPAC to take consumer DNA testing company 23andMe public in a massive deal.
It was a busy week for clinical trial updates. Here’s a look.
Treatments for HIV are poised for another breakthrough. Researchers at Washington University in St. Louis (WUSTL) have discovered a way to eradicate dormant HIV virus within the cells, before it becomes active.
The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.
China’s Clover Biopharmaceuticals is spurning GlaxoSmithKline’s adjuvant vaccine technology in favor of one created by California-based Dynavax Technologies.
The pharmaceutical industry continues to demonstrate its willingness to team up in the ongoing combat against the global COVID-19 pandemic.
JOBS
IN THE PRESS